Douglas Black

Professor

Department of Pharmacy, Pharmacy Faculty, School Faculty

Telephone: (206) 685-0941

Email: dblack@uw.edu

Office Location: H-375U Health Sciences Building

Expertise:

Education

  • Doctor of Pharmacy (UW, 1983)

Research Interests

  • Antibiotic resistance
  • Infectious disease pharmacotherapy
  • Drug interactions

Courses Taught

  • PHARM 519
  • PHARM 559
  • PHARM 579
  • PHRMCY 532

Biography

Douglas Black is a Professor at the University of Washington School of Pharmacy. He earned his Doctor of Pharmacy from the UW in 1983. During 1983-1989 he served as oncology pharmacist for the UW Medical Center, participating in the design, completion, and analysis of two febrile neutropenia antibiotic trials. Doug has provided pharmacy consultation to the UW General Infectious Disease service for almost 30 years, instructing hundreds of pharmacy students and residents on the pharmacokinetics and pharmacodynamics of antimicrobial agents and collaborating with infectious disease physicians on multiple projects involving antibiotic resistance and the pharmacokinetics of drug interactions. Doug has served as contributing editor in pharmacology for The Sanford Guide to Antimicrobial Therapy since 2010.

Selected Publications

  • Baradaran S, Black DJ, Keyloun KR, Hansen RN, Gillard PJ, Devine EB. The impact of acute kidney injury on the risk of mortality and healthcare utilization among patients treated with polymyxins for severe gram negative infections. Open Forum Infect Dis 5(8):ofy191, 2018.
  • Chow S-K, Jain R, Black D, Pottinger PS, Fang FC, Butler-Wu SM. The devil is in the details: impact of penicillin susceptibility reporting on the treatment of streptococcal infective endocarditis. Clin Infect Dis 2016; 62: 264-5.
  • Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA, Hooton TM. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrob Agents Chemother 49 (4): 1649-51, 2005.
  • Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-625.
  • Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-428.